ATL2

Across TCGA pan-cancer cohorts, ATL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATL2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATL2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where ATL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.520	0.224	.002	24	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	18	view →
PDAC	DFS	Quartile	All	0.659	0.837	.017	6	view →
LSCC	OS	Median	All	1.000	0.937	.011	6	view →
HNSC	DFS	Quartile	II,III,IV	0.802	0.653	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATL2–GBM (DFS)

Open the GBM breakdown →